Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect… Ended

2023-503797-21-00 Metastatic Colorectal Cancer 5 2022-08-10
A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SU… Ended

2024-516290-67-00 ADVANCED SOLID TUMORS AND LYMPHOMA 9 2022-08-03
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai… Ended

2024-516061-36-00 Newly diagnosed patients with multiple myeloma and seve 4 2022-07-28
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Ended

2023-506402-39-00 Advanced cancer of different organs 1 2022-07-27
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian… Ended

2023-505005-16-00 Primary peritoneal cancer/Fallopian tube cancer 4 2022-07-27
Extracorporeal photopheresis as treatment for immune related adverse events after immunotherapy Ended

2024-513614-36-00 Immune related adverse events induced by treatment with 9 2022-07-27
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone … Ended

2024-516661-37-00 Metastatic Prostate Cancer 3 2022-07-27
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ended

2023-509095-42-00 Colorectal cancer 4 2022-07-14
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours Ended

2024-512866-32-00 Solid tumors 7 2022-07-12
Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance… Ended

2024-514293-46-00 Unresectable locally advanced or metastatic urothelial 4 2022-07-07
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk… Ended

2023-508357-58-00 Acute lymphocytic leukaemia- Acute myeloid leukaemia re 7 2022-07-04
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Solid tumours 9 2022-06-29
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended

2023-504441-31-00 gastric adenocarcinoma or adenocarcinoma of the gastroe 7 2022-06-29
A Study of MK-1088 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors Ended

2022-502288-40-00 Treatment of advanced/metastatic solid tumors 4 2022-06-29
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended

2023-506380-33-00 Early or Locally Advanced/ Inflammatory HER2-Positive B 5 2022-06-28
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination… Ended

2024-511744-27-00 Solid tumors, Non-Small Cell Lung Cancer, Cervical Canc 1 2022-06-27
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a C… Ended

2024-514532-24-00 Solid cancer tumors 3 2022-06-23
A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re… Ended

2023-507140-37-00 Adult patients with relapsed and refractory multiple my 4 2022-06-22
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination… Ended

2024-511352-41-00 advanced solid tumors 3 2022-06-13
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo… Ended

2024-510644-31-00 Relapsed/Refractory Multiple Myeloma 3 2022-06-10
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovari… Ended

2024-516166-11-00 Platinum resistant recurrent or metastatic ovarian, fal 5 2022-06-06
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Ended

2024-511286-11-00 Advanced Solid Tumors 1 2022-06-03
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Tr… Ended

2024-511561-10-00 Metastatic Squamous Cell Carcinoma of Head and Neck (SC 4 2022-05-31